Biofrontera Inc BFRI
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-14 |
| Shares Out. | 12,800,000 |
| Website | biofrontera-us.com/ ↗ |
| Phone | 17812451325 |
| Employees | 94 |
| Revenue | $10.1M |
| Gross Profit | $8.0M |
| Net Income | -$4.8M |
| Free Cash Flow | -$9.3M |
| Total Assets | $24.8M |
| Total Liabilities | $18.7M |
| Equity | $6.1M |
About Biofrontera Inc
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Biofrontera Inc is a publicly traded company under the ticker symbol BFRI on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)